CD8A and cancer: In another study, Gu et al. improved the targeting of anti‐programmed cell death protein ligand‐1 (PD‐L1) antibody through conjugation with platelet‐derived microparticles (PMPs).[101] This approach likewise enhanced CD4+ and CD8+ T cell trafficking, reduced cancer growth and metastasis, and prolonged the survival of tumor‐bearing mice (B16‐F10 and 4T1).